Les nouveaux médicaments en diabétologie et en endocrinologie

New anti-diabetic drugs are regularly becoming available, in particular Glucagon-like peptide-1 (GLP-1) receptor agonists. In 2016, a new selective oestrogen receptor modulator, acting in the uterus as an oestrogen receptor antagonist, which considerably reduces the risk caused by oestrogen of endometrial hyperplasia in women with an intact uterus, have also arrived on the market.